These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 24993933)

  • 1. Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial design.
    Pond GR; Bellmunt J; Rosenberg JE; Bajorin DF; Regazzi AM; Choueiri TK; Qu AQ; Niegisch G; Albers P; Necchi A; Di Lorenzo G; Fougeray R; Wong YN; Sridhar SS; Ko YJ; Milowsky MI; Galsky MD; Sonpavde G
    Clin Genitourin Cancer; 2015 Feb; 13(1):71-9. PubMed ID: 24993933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma.
    Sonpavde G; Pond GR; Rosenberg JE; Bajorin DF; Regazzi AM; Choueiri TK; Qu AQ; Niegisch G; Albers P; Necchi A; Di Lorenzo G; Fougeray R; Dreicer R; Chen YH; Wong YN; Sridhar SS; Ko YJ; Milowsky MI; Galsky MD; Bellmunt J
    Clin Genitourin Cancer; 2015 Apr; 13(2):185-92. PubMed ID: 25458370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.
    Sonpavde G; Pond GR; Choueiri TK; Mullane S; Niegisch G; Albers P; Necchi A; Di Lorenzo G; Buonerba C; Rozzi A; Matsumoto K; Lee JL; Kitamura H; Kume H; Bellmunt J
    Eur Urol; 2016 Apr; 69(4):634-641. PubMed ID: 26264159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design.
    Pond GR; Bellmunt J; Fougeray R; Choueiri TK; Qu AQ; Niegisch G; Albers P; Di Lorenzo G; Salhi Y; Galsky MD; Agarwal N; Necchi A; Sonpavde G
    Clin Genitourin Cancer; 2013 Dec; 11(4):495-500. PubMed ID: 23800847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma.
    Sonpavde G; Pond GR; Di Lorenzo G; Buonerba C; Rozzi A; Lanzetta G; Necchi A; Giannatempo P; Raggi D; Matsumoto K; Choueiri TK; Mullane S; Niegisch G; Albers P; Lee JL; Kitamura H; Kume H; Bellmunt J
    Clin Genitourin Cancer; 2016 Dec; 14(6):494-498. PubMed ID: 27262369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.
    Sonpavde G; Pond GR; Fougeray R; Choueiri TK; Qu AQ; Vaughn DJ; Niegisch G; Albers P; James ND; Wong YN; Ko YJ; Sridhar SS; Galsky MD; Petrylak DP; Vaishampayan UN; Khan A; Vogelzang NJ; Beer TM; Stadler WM; O'Donnell PH; Sternberg CN; Rosenberg JE; Bellmunt J
    Eur Urol; 2013 Apr; 63(4):717-23. PubMed ID: 23206856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin.
    Locke JA; Pond GR; Sonpavde G; Necchi A; Giannatempo P; Paluri RK; Niegisch G; Albers P; Buonerba C; Di Lorenzo G; Vaishampayan UN; North SA; Agarwal N; Hussain SA; Pal S; Eigl BJ
    Clin Genitourin Cancer; 2016 Aug; 14(4):331-40. PubMed ID: 26589729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma.
    Sonpavde G; Pond GR; Rosenberg JE; Bajorin DF; Choueiri TK; Necchi A; Di Lorenzo G; Bellmunt J
    J Urol; 2016 Feb; 195(2):277-82. PubMed ID: 26292040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Third-Line Chemotherapy for Metastatic Urothelial Cancer: A Retrospective Observational Study.
    Di Lorenzo G; Buonerba C; Bellelli T; Romano C; Montanaro V; Ferro M; Benincasa A; Ribera D; Lucarelli G; De Cobelli O; Sonpavde G; De Placido S
    Medicine (Baltimore); 2015 Dec; 94(51):e2297. PubMed ID: 26705213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of multimodal treatment on survival in patients with metastatic urothelial cancer.
    Abe T; Shinohara N; Harabayashi T; Sazawa A; Maruyama S; Suzuki S; Nonomura K
    Eur Urol; 2007 Oct; 52(4):1106-13. PubMed ID: 17367917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of survival in patients with metastatic urothelial carcinoma: A multi-institutional study.
    Taguchi S; Nakagawa T; Matsumoto A; Nagase Y; Kawai T; Tanaka Y; Yoshida K; Yamamoto S; Enomoto Y; Nose Y; Sato T; Ishikawa A; Uemura Y; Fujimura T; Fukuhara H; Kume H; Homma Y
    Int J Urol; 2015 Jul; 22(7):638-43. PubMed ID: 25903328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy.
    Galsky MD; Moshier E; Krege S; Lin CC; Hahn N; Ecke T; Sonpavde G; Pond G; Godbold J; Oh WK; Bamias A
    Urol Oncol; 2014 Jan; 32(1):48.e1-8. PubMed ID: 24055428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab.
    Kobayashi T; Ito K; Kojima T; Kato M; Kanda S; Hatakeyama S; Matsui Y; Matsushita Y; Naito S; Shiga M; Miyake M; Muro Y; Nakanishi S; Kato Y; Shibuya T; Hayashi T; Yasumoto H; Yoshida T; Uemura M; Taoka R; Kamiyama M; Ogawa O; Kitamura H; Nishiyama H;
    Cancer Sci; 2021 Feb; 112(2):760-773. PubMed ID: 33283385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study.
    Vaishampayan UN; Faulkner JR; Small EJ; Redman BG; Keiser WL; Petrylak DP; Crawford ED
    Cancer; 2005 Oct; 104(8):1627-32. PubMed ID: 16138364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-line Chemotherapy in Older Patients With Metastatic Urothelial Carcinoma: Pooled Analysis of 10 Second-line Studies.
    Salah S; Lee JL; Rozzi A; Kitamura H; Matsumoto K; Vis DJ; Srinivas S; Morales-Barrera R; Carles J; Al-Rimawi D; Lee S; Kim KH; Izumi K; Lewin J
    Clin Genitourin Cancer; 2017 Aug; 15(4):e563-e571. PubMed ID: 28065418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of gender on outcomes in patients with metastatic urothelial carcinoma.
    Haines L; Bamias A; Krege S; Lin CC; Hahn N; Ecke TH; Moshier E; Sonpavde G; Godbold J; Oh WK; Galsky MD
    Clin Genitourin Cancer; 2013 Sep; 11(3):346-52. PubMed ID: 23673281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postchemotherapy lymphadenectomy in patients with metastatic urothelial carcinoma: long-term efficacy and implications for trial design.
    Necchi A; Giannatempo P; Lo Vullo S; Farè E; Raggi D; Nicolai N; Piva L; Biasoni D; Torelli T; Catanzaro M; Stagni S; Maffezzini M; Mariani L; Salvioni R
    Clin Genitourin Cancer; 2015 Feb; 13(1):80-86.e1. PubMed ID: 25027186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive factors of response to cisplatin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer.
    Sengeløv L; Kamby C; Geertsen P; Andersen LJ; von der Maase H
    Cancer Chemother Pharmacol; 2000; 46(5):357-64. PubMed ID: 11127939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel Carboplatin chemotherapy as a second-line chemotherapy for advanced platinum resistant urothelial cancer in Japanese cases.
    Soga N; Onishi T; Arima K; Sugimura Y
    Int J Urol; 2007 Sep; 14(9):828-32. PubMed ID: 17760750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy.
    Shinohara N; Harabayashi T; Suzuki S; Nagao K; Seki H; Murakumo M; Mitsuhashi K; Demura T; Nagamori S; Matsuyama H; Naito K; Nonomura K
    Cancer Chemother Pharmacol; 2006 Sep; 58(3):402-7. PubMed ID: 16416335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.